Richard Axel, M.D.
Physician-scientist with 20 years of experience performing impactful translational cancer research and early-stage drug development. Dr. Mintz has developed anticancer therapies that have resulted in over 100 publications, presentations and patents. He has obtained millions of dollars in federal and foundation grants to support bringing novel, early-stage therapeutics to clinic and has extensive experience in early stage drug development.
Chief Medical Officer
Brian has more than 20 years of experience in developing precision medicine, especially in the field of oncology.
Prior to joining Cornerstone, Brian was the Global Head of Clinical Affairs, Oncology Precision Medicine / Companion Diagnostics at Novartis; Senior Director, Oncology Translational Medicine at Eli Lilly; Director, Oncology Clinical Development at Bristol-Myers Squibb and Medical Director at Myriad Genetics
At Cornerstone, Brian is responsible for clinical development of Cornerstone’s platform technology. He will guide the clinical development of Cornerstone’s lead compound, CPI-613, as well as the other promising compounds in pipeline.
Timothy S. Pardee
Timothy S. Pardee,
Associate professor and the Director of Leukemia Translational Research at the Comprehensive Cancer Center of Wake Forest Baptist Medical Center. Dr. Pardee heads an NCI-funded research program focused on the role of cellular metabolism in cancer cell survival and resistance to therapy as well as novel therapeutics. He has played a lead role in the development of the novel metabolism-targeting agent CPI-613.
404 Error! Page not found
Page not found